SANDU PHARMACEUTICALS LTD.

Sandu Pharmaceuticals Ltd received a demand order from the Assistant Commissioner due to discrepancies between invoice quantity and physical verification of goods in Uttar Pradesh. The company accepted the liability and paid a penalty of ₹31,699 on May 6, 2026. Consequently, the GST authority dropped the proceedings, and the company anticipates no major impact.

Sandu Pharmaceuticals Ltd has filed a statement of deviation and variation of funds for the quarter ended March 31, 2026, as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The filing pertains to preferential issues of equity shares via private placement in 2021 and 2022. The audit committee has reviewed and approved the statement, and the auditors have provided no comments. There was no deviation or variation in the use of funds raised.

The Board of Directors of Sandu Pharmaceuticals Limited approved a final dividend of ₹1 per equity share for the financial year 2025-26, as of March 31, 2026. The dividend is subject to the approval of shareholders at the upcoming Annual General Meeting (AGM). The date of the AGM, the record date for determining eligibility for the dividend, and the dividend payout date will be announced later.

Sandu Pharmaceuticals Ltd re-appointed Internal Auditors and Cost Auditor for the financial year 2026-27 during its Board Meeting held on May 5, 2026. The board also approved the standalone audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of ₹1 per equity share (10% on paid-up share capital), subject to shareholder approval. M/s Shekhar Joshi & Co was appointed as the Cost Auditor, while M/S Akhil Pai & Co and M/S Uday & Uday Associates were appointed as Internal Auditors for Goa and Mumbai operations, respectively.

Sandu Pharmaceuticals Ltd's board meeting on May 5, 2026, approved standalone audited financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹1 per equity share (10% on paid-up capital) subject to shareholder approval. M/s Shekhar Joshi & Co was appointed as the Cost Auditor for FY 2026-27. Additionally, M/S Akhil Pai & Co and M/S Uday & Uday Associates were appointed as internal auditors for Goa and Mumbai plants, respectively.

Sandu Pharmaceuticals Ltd announced audited financial results for the quarter and year ended March 31, 2026, following a Board Meeting on May 5, 2026. The board approved the standalone audited financial results and recommended a final dividend of ₹1 per equity share (10% on paid-up share capital), subject to shareholder approval. They also appointed M/s Shekhar Joshi & Co as Cost Auditor for FY 2026-27 and M/S Akhil Pai & Co and M/S Uday & Uday Associates as Internal Auditors for Goa and Mumbai plants respectively. The board also took note of the Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015.

Sandu Pharmaceuticals Ltd has announced that its Board of Directors will convene a meeting on Tuesday, May 5, 2026. The primary agenda for this meeting is to recommend, discuss, or suggest a final dividend for the financial year that concluded on March 31, 2026. Any proposed dividend will be subject to the approval of the shareholders at the forthcoming Annual General Meeting.

Sandu Pharmaceuticals Ltd announced that its Board of Directors will convene on May 5, 2026, at 3:00 p.m. at the Corporate Office in Mumbai. The primary agenda includes the consideration and approval of the Standalone Audited Financial Results for the quarter and financial year ended March 31, 2026. Additionally, the Board will discuss and potentially recommend a final dividend for the financial year ended March 31, 2026. In compliance with insider trading regulations, the trading window for the company's directors, officers, and designated employees has been closed from April 1, 2026, and will remain closed until 48 hours after the public announcement of the financial results.

Sandu Pharmaceuticals Ltd has announced the closure of the trading window for the quarter ended 31st March 2026. The closure is in accordance with the 'Code of Conduct for Prevention of Insider Trading' of the company, SEBI (Prohibition of Insider Trading) Regulations, 2015, and a clarification given by BSE. The trading window will remain closed from Wednesday, 01 April 2026 till 48 hours after the declaration of the financial results of the company for the quarter and year ended 31st March 2026. This restriction applies to Directors, KMPs, Promoters, and Promoters Group, Designated Persons, and their immediate relatives covered under the Code. The date of the Board Meeting for consideration of the Audited Financial Results of the Company for the Quarter and Year ended 31 March 2026 will be intimated in due course.

Sandu Pharmaceuticals Ltd. has reported no deviation in the use of funds raised from the preferential issue. The funds have been utilized towards the revamping of existing capital machinery, developing marketing infrastructure, and purchase of new/additional plant and machinery. The company also allocated funds for working capital requirements, investment in technologies, and general purposes.